Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Over 8.8?million Indians aged 60 and above currently live with dementia,
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Subscribe To Our Newsletter & Stay Updated